stoxline Quote Chart Rank Option Currency Glossary
Protagonist Therapeutics, Inc. (PTGX)
37.805  1.055 (2.87%)    07-16 12:43
Open: 36.89
High: 37.885
Volume: 218,655
Pre. Close: 36.75
Low: 36.8
Market Cap: 2,217(M)
Technical analysis
2024-07-16 12:22:57 PM
Short term     
Mid term     
Targets 6-month :  44.18 1-year :  51.6
Resists First :  37.83 Second :  44.18
Pivot price 34.55
Supports First :  33.4 Second :  30.67
MAs MA(5) :  36.22 MA(20) :  33.95
MA(100) :  30 MA(250) :  23.89
MACD MACD :  1.3 Signal :  1.1
%K %D K(14,3) :  93.3 D(3) :  89.9
RSI RSI(14): 71.3
52-week High :  37.83 Low :  13.72
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ PTGX ] has closed below upper band by 3.7%. Bollinger Bands are 27% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 37.14 - 37.27 37.27 - 37.39
Low: 35.97 - 36.13 36.13 - 36.29
Close: 36.49 - 36.72 36.72 - 36.93
Company Description

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Headline News

Sun, 14 Jul 2024
The 7.1% return this week takes Protagonist Therapeutics' (NASDAQ:PTGX) shareholders five-year gains to 175% - Simply Wall St

Fri, 12 Jul 2024
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Sees Significant Decline in Short Interest - MarketBeat

Fri, 12 Jul 2024
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 12-Month High at $35.99 - MarketBeat

Thu, 27 Jun 2024
Is Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy? - Insider Monkey

Thu, 27 Jun 2024
Protagonist Therapeutics Set to Join S&P SmallCap 600 - Longview News-Journal

Sun, 09 Jun 2024
Do Its Financials Have Any Role To Play In Driving Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock Up Recently? - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 59 (M)
Shares Float 43 (M)
Held by Insiders 1.1 (%)
Held by Institutions 104.1 (%)
Shares Short 3,120 (K)
Shares Short P.Month 3,470 (K)
Stock Financials
EPS 2.53
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.56
Profit Margin 51.4 %
Operating Margin 80.9 %
Return on Assets (ttm) 21.3 %
Return on Equity (ttm) 41.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 5.36
EBITDA (p.s.) 2.55
Qtrly Earnings Growth 0 %
Operating Cash Flow -63 (M)
Levered Free Cash Flow -155 (M)
Stock Valuations
PE Ratio 14.83
PEG Ratio 0
Price to Book value 3.94
Price to Sales 7.01
Price to Cash Flow -34.92
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android